The New England Journal of Medicine November 30, 2006

CD4+ Count-Guided Interruption of Antiretroviral Treatment

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group

Bottom Line

Episodic, CD4+ count-guided interruption of antiretroviral therapy significantly increases the risk of opportunistic disease, death, and major non-AIDS-related complications compared to continuous therapy.

Key Findings

1. The primary endpoint (opportunistic disease or death) occurred in 120 participants (3.3 events per 100 person-years) in the episodic ART group vs. 47 participants (1.3 per 100 person-years) in the continuous ART group (HR 2.6; 95% CI, 1.9-3.7; P<0.001) [1.1.2].

2. Episodic therapy significantly increased the risk of death from any cause compared to continuous therapy (HR 1.8; 95% CI, 1.2-2.9; P=0.007).

3. Major non-AIDS defining events, including cardiovascular, renal, and hepatic disease, were significantly more frequent in the episodic ART group (HR 1.7; 95% CI, 1.1-2.5; P=0.009).

4. Adjusting for the time-updated CD4+ count and HIV RNA level reduced the hazard ratio for the primary endpoint from 2.6 to 1.5, indicating that the excess risk was largely driven by declining CD4+ counts and rebounding viremia during interruptions.

Study Design

Design

RCT

Open-Label

Sample

5,472

Patients

Duration

16 mo

Median

Setting

33 countries

Population Persons infected with HIV who had a CD4+ cell count of more than 350 cells per cubic millimeter.

Intervention Episodic antiretroviral therapy (drug conservation): therapy deferred until CD4+ count decreased to <250 cells/mm3 and then used until CD4+ count increased to >350 cells/mm3.

Comparator Continuous use of antiretroviral therapy (viral suppression group).

Outcome Development of an opportunistic disease or death from any cause.

Study Limitations

• Early termination of the trial (after an average follow-up of 16 months) limited the ability to assess long-term drug toxicities and outcomes over the originally planned duration [1.1.2].

• The open-label design could theoretically introduce diagnostic or reporting bias for certain clinical endpoints, although major events were centrally adjudicated.

• The study tested specific CD4 thresholds (<250 cells/mm3 to restart, >350 cells/mm3 to stop); while unlikely to change the overall conclusion, it left unexamined whether different thresholds might have altered the risk profile.

Clinical Significance

The SMART trial fundamentally changed HIV management by demonstrating that structured treatment interruptions are harmful, causing both AIDS-related and non-AIDS-related morbidity and mortality. This paradigm-shifting result ended the practice of 'drug holidays' and established that continuous viral suppression is essential, partly by showing that uncontrolled HIV replication drives systemic inflammation leading to cardiovascular, renal, and hepatic disease.

Historical Context

In the early to mid-2000s, combination antiretroviral therapy was fraught with significant toxicities, high pill burdens, and costs. Consequently, structured treatment interruptions (STIs) were theorized as a way to minimize drug exposure while maintaining immune function. The SMART trial was launched to definitively test this widely debated strategy but was halted prematurely when it became unequivocally clear that continuous viral suppression was vastly superior to episodic treatment.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why might interrupting ART lead to an increase in non-AIDS complications like myocardial infarction and renal disease, even if the CD4+ count remains above the threshold for opportunistic infections?

Key Response

Tests understanding of HIV pathophysiology beyond immunodeficiency. HIV viremia causes chronic systemic inflammation, endothelial dysfunction, and monocyte/macrophage activation, driving atherogenesis and end-organ damage independent of CD4 count drops.

Resident

A patient with a CD4+ count of 800 cells/mm3 on stable ART complains of medication fatigue and asks if they can take a 'drug holiday' until their CD4 drops below 350. Based on the SMART trial, how should you counsel this patient regarding the specific risks of stopping therapy?

Key Response

Applies the study directly to patient counseling. The resident must explain that treatment interruption increases not only the risk of progression to AIDS but significantly increases the risk of cardiovascular events, liver disease, and death, ruling out 'drug holidays' as a safe management strategy.

Fellow

The SMART trial revealed unexpected increases in cardiovascular and hepatic events during ART interruption. How did this paradigm-shifting finding change our understanding of ART toxicity versus the toxicity of untreated HIV viremia, and how does this influence modern ART selection in patients with metabolic comorbidities?

Key Response

Explores the shift in dogma. Before SMART, providers worried ART toxicity caused CVD/metabolic issues. SMART showed untreated HIV is far more toxic to the vascular endothelium. Fellows must balance ART side effects with the critical need for continuous viral suppression, choosing lipid-neutral/renal-safe regimens rather than stopping ART.

Attending

Given that the SMART trial definitively ended the practice of CD4-guided treatment interruptions, how do its findings regarding viral-mediated inflammation continue to influence our approach to 'elite controllers' or patients with low-level viremia but preserved CD4 counts?

Key Response

Connects historical trial data to modern dilemmas. Even if CD4 is preserved, ongoing viremia drives systemic inflammation. This study provides the foundational logic for treating all patients with HIV regardless of CD4 count, including elite controllers who exhibit signs of immune activation.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The SMART trial was stopped early by the Data and Safety Monitoring Board (DSMB) due to a clear safety signal in the drug conservation arm. How does early trial termination for harm affect the precision of effect size estimates for secondary endpoints (like specific non-AIDS events), and what statistical methods are required to account for this truncation?

Key Response

Focuses on clinical trial methodology. Stopping early for harm or benefit can lead to exaggerated effect sizes (random high) and limits the statistical power for secondary endpoints, requiring careful survival analysis and penalization techniques to avoid overstating specific risks.

Journal Editor

As a reviewer evaluating the SMART trial's composite primary endpoint (opportunistic disease or death from any cause), what potential biases arise when combining an expected, HIV-specific outcome (opportunistic disease) with broad, non-specific outcomes (all-cause mortality) in an open-label trial design?

Key Response

Questions composite endpoint design and open-label bias. Open-label status might influence how aggressively non-AIDS conditions are investigated or diagnosed, although all-cause mortality is objective. The reviewer must scrutinize if the composite endpoint masks the specific drivers of the outcome.

Guideline Committee

The SMART trial provided pivotal Level A evidence that shifted HIV guidelines away from CD4-guided initiation and interruption. How do the SMART findings directly support the current DHHS guideline recommendation for universal, continuous ART regardless of CD4 count, specifically regarding the prevention of non-AIDS defining conditions?

Key Response

Links the trial to current DHHS guidelines (ART for all). The trial proved that waiting for CD4 to drop or interrupting therapy harms patients via non-AIDS events (CVD, renal, hepatic). Thus, continuous suppression is recommended to mitigate systemic inflammation, forming the bedrock of the 'treat all' guideline.

Clinical Landscape

Noteworthy Related Trials

2006

STACCATO Trial

n = 430 · Lancet

Tested

CD4-guided scheduled treatment interruptions

Population

HIV-positive patients with virologic suppression on ART

Comparator

Continuous antiretroviral therapy

Endpoint

Proportion of patients with virologic failure or resistance

Key result: CD4-guided interruptions were associated with a higher rate of virologic failure and non-nucleoside reverse transcriptase inhibitor resistance.

2006

TRIVACAN Trial

n = 326 · Lancet

Tested

CD4-guided ART interruption

Population

HIV-positive adults on suppressive ART in a resource-limited setting

Comparator

Continuous ART

Endpoint

Severe HIV-related morbidity or mortality

Key result: The CD4-guided interruption arm experienced a 2.5-fold higher rate of severe HIV-related morbidity compared to continuous ART.

2015

START Trial

n = 4,685 · NEJM

Tested

Immediate initiation of ART

Population

HIV-positive adults with CD4+ count > 500 cells/mm3

Comparator

Deferred ART initiation until CD4+ < 350 cells/mm3

Endpoint

Serious AIDS-related or non-AIDS-related event, or death

Key result: Immediate ART initiation significantly reduced the risk of the primary composite endpoint compared to deferred initiation.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis